

Pertuzumab ; 帕妥珠单抗

产品编号 : MB2762

质量标准 : >95%,蛋白原液

包装规格 : 1MG/5MG

产品形式 :

基本信息

分子式	N/A
分子量	145.17KD
CAS NO	380610-27-5
储存条件	-70 ± 15°C for long-term storage, 2-8°C for short-term storage, away from light

简介: Pertuzumab, a humanized monoclonal antibody, is a HER2 dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.

产品形式: 蛋白原液。每种装于冻存管中, 单抗质量为标示数量 1MG 或者 5MG, 体积根据其浓度不同略有不同。

质量标准:

Non-reduced CE-SDS:.....>90%;

SEC-HPLC:.....>95%;

Bacterial Endotoxins Test:<10EU/ml

Residual Proteins of HostCell:<100 ng/mg

Exogenous residual DNA:<100pg/mg

Residual Protein A:<100 ng/mg

Biological Activity:.....80% to 125% of standard

储存条件: -70 ± 15°C for long-term storage, 2-8°C for short-term storage, away from light.

使用建议:

meilunbio 提供的产品为蛋白原液形式。每种装于冻存管中, 单抗质量为标示数量 1MG 或者 5MG, 体积根据其浓度不同略有不同。

使用前可以根据自己实验需求进行稀释, 溶剂建议用去离子无菌水(meilunbio 货号 MA0028, 去离子无菌水(细胞培养用水))或者 PBS (meilunbio 货号 MA0015PBS(1X), 细胞培养级)。

不建议使用含有防腐成分的稀释液进行稀释, 会增加细胞或者动物毒性。

稀释前，计算加入多少体积溶剂，请参考购买批次质检单上蛋白浓度，或者询问我司，

举例，质检单显示该批次单抗蛋白原液蛋白浓度为 50mg/ml

对应 5MG 包装的蛋白原液体积为 $5\text{mg (质量)} / 50\text{mg/ml(浓度)} = 0.1\text{ML}$ ，

实验需求蛋白浓度为 10mg/ml, 需要稀释倍数为 $50/10=5$, 则需要加入 0.4ML, 即 400ul PBS 或者无菌去离子水即可。

若给药量为固定质量值，比如单次给药 0.5MG，对应蛋白原液给药体积为 10ul，建议稀释后，提高给药体积降低误差，因为注射器或者移液器吸头残留会影响实验效果。

稀释后的蛋白溶液，可于 2-8 度冷藏避光保存不超过 2 周，不建议长期储存。

避免反复冻融，每次冻融蛋白活性会降低约 5% 左右。

生物活性（仅来自于公开文献，不保证其有效性）

描述	Pertuzumab, a humanized monoclonal antibody, is a HER2 dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.
靶点	HER2
体外	Trastuzumab and Pertuzumab are highly synergistic inhibitors of BT474 breast cancer cell survival. The combination of trastuzumab and Pertuzumab mediates a loss of up to 60% of cells at doses in which individual drugs do not alter cell survival. The combination of trastuzumab and Pertuzumab reduces the percentage of proliferating (S-phase) cells by more than 2-fold. A combination of trastuzumab and Pertuzumab inhibits cell proliferation and survival to a greater degree than does either agent alone.
体内	In Calu-3 NSCLC xenografts, monotherapy with pertuzumab or trastuzumab is able to significantly inhibit tumor growth, with treatment-to-control ratios (TCR) of 0.23 and 0.27, respectively. The combination of trastuzumab and pertuzumab produces a dramatically enhanced antitumor activity compared with single-agent treatments (TCR 0.05, resulting in tumor regression and, in 3 of 10 animals, complete tumor remission). Treatment of KPL-4 breast cancer xenografts with either trastuzumab or pertuzumab inhibits tumor growth with TCRs of 0.67 and 0.65, respectively. Pertuzumab maintains antitumor activity after progression on trastuzumab.

美仑相关产品推荐(更多相关靶点抑制剂请详询官网或客服)

产品编号	品名.	Target
MB2806	aflibercept	VEGFR
MB2786	Alemtuzumab	CD52
MB2787	Alirocumab	PCSK9
MB2789	Avelumab	PDL-1
MB2790	Atezolizumab	PDL-1
MB2791	Bevacizumab	VEGF
MB2792	Cetuximab	EGFR
MB2803	Daratumumab	CD38

MB2794	Denosumab	RANK Ligand
MB2023	Eculizumab	补体蛋白(C5)
MB2795	Etanercept	TNF
MB2797	Evolocumab	PCSK9
MB2773	Infliximab	TNF- α
MB2769	Ipilimumab	CTLA-4
MB2772	Matuzumab	EGFR
MB2766	Mepolizumab	IL-5
MB2767	Nivolumab	PD-1
MB2774	Obinutuzumab	CD20
MB2776	Ofatumumab	CD20
MB2777	Omalizumab	IgE
MB2781	Panitumumab	EGFR
MB2761	Pembrolizumab	PD-1
MB2784	Adalimumab	TNF- α
MB2763	Ranibizumab	VEGFR
MB2938	Ramucirumab	VEGFR
MB2749	Rituximab	CD20
MB2757	Secukinumab	IL-17
MB2751	Tocilizumab/Atlizumab	IL-6 receptor
MB2753	Trastuzumab	ErbB2
MB2758	Ustekinumab	IL-12

用途及描述: 仅供科研, 严禁用于人体(For R&D Only)